Tivozanib Hydrochloride + paclitaxel + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Triple Negative Breast Cancer
Conditions
Triple Negative Breast Cancer
Trial Timeline
Nov 1, 2012 → Jun 1, 2014
NCT ID
NCT01745367About Tivozanib Hydrochloride + paclitaxel + Placebo
Tivozanib Hydrochloride + paclitaxel + Placebo is a phase 2 stage product being developed by Astellas Pharma for Triple Negative Breast Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01745367. Target conditions include Triple Negative Breast Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Triple Negative Breast Cancer were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01745367 | Phase 2 | Terminated |
Competing Products
20 competing products in Triple Negative Breast Cancer